Litigation Details for Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited and Camber Pharmaceuticals, Inc. (D. Del. 2021)
✉ Email this page to a colleague
Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited and Camber Pharmaceuticals, Inc. (D. Del. 2021)
| Docket | ⤷ Try a Trial | Date Filed | 2021-02-10 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | Defendant | Referred To | |
| Parties | AZURITY PHARMACEUTICALS, INC. | ||
| Patents | 10,039,745; 10,154,987; 6,028,222; 6,977,257; 8,568,747; 8,778,366; 9,000,002; 9,000,011; 9,463,183; 9,616,096; 9,669,008; 9,808,442; 9,855,214; 9,968,553 | ||
| Attorneys | Todd S. Werner | ||
| Firms | Young, Conaway, Stargatt & Taylor LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited and Camber Pharmaceuticals, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited and Camber Pharmaceuticals, Inc.
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Limited and Camber Pharmaceuticals, Inc. (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-01-10 | 89 | U.S. patent application Ser. No. 15/802,341, filed Nov. 2, 2017 (now U.S. Pat. No. 10,039,745, issued… U.S. patent application Ser. No. 15/802,341, filed Nov. 2, 2017 (now U.S. Pat. No. 10,039,745, issued…claims of U.S. Patent Nos. 10,772,868 (“the ’868 patent”), and 10,799,476 (“the ’476 patent”) (collectively…The ’868 Patent The ’868 patent is entitled “Enalapril Formulations.” The ’868 patent issued …The ’476 Patent The ’476 patent is entitled “Enalapril Formulations.” The ’476 patent issued on | External link to document | |
| 2022-01-10 | 90 | Redacted Document | disclosed in U.S. Patent Nos. 9,669,008 (the “’008 patent”); 9,808,442; 10,039,745; and 10,154,987,…regarding U.S. Patent Nos. 10,772,868 (the “’868 patent”) and 10,799,476 (the “’476 patent’”) (collectively…476 patents are continuations in the ’008 patent family. The ’008, ’868, and ’476 patents all share… ’476 patent, as well as any patents within this family. 35. The Asserted Patents are directed… 8. ’747 Patent 136. U.S. Patent No. 8,568,747 (the “’747 Patent”) (ANNENAL00005470 | External link to document |
| 2022-01-10 | 92 | U.S. Pat. No. 10,039,745, issued Aug. 7, 2018), which is a continuation of U.S. patent application Ser…U.S. patent application Ser. No. 15/802,341, filed Nov. 2, 2017 (now U.S. Pat. No. 10,039,745, issued… OTHER PUBLICATIONS 10,039,745, which is a continuation of application …Rosati, P.C. Nov. 2, 2017, now Pat. No. 10,039,745, which is a continuation of application…dictionary.thefreedictionary.com/hypertension (2008). 10,039,745 | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
